Evidence map›Paper›PMID 25971798›Full record

ArticleMolecular biology of the cell2015

Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments.

Galina Schevzov, Anthony J Kee, Bin Wang, Vanessa B Sequeira, Jeff Hook, Jason D Coombes, Christine A Lucas, Justine R Stehn, Elizabeth A Musgrove, Alexandra Cretu and 8 more

Open access · greenAbstract read
In one paragraph

Article in Molecular biology of the cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Impact of Black Soldier Fly Larvae Oil on Immunometabolic Processes.International journal of molecular sciences · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Research Advances in the Role of the Tropomyosin Family in Cancer.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Galina SchevzovOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Anthony J KeeCellular and Genetic Medicine Unit, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Bin WangOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Vanessa B SequeiraOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Jeff HookOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Jason D CoombesOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.
Christine A LucasCellular and Genetic Medicine Unit, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Justine R StehnOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Elizabeth A MusgroveKinghorn Cancer Centre, Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW 2010, Australia.
Alexandra CretuDepartment of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160.
Richard AssoianDepartment of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160.
Thomas FathNeurodegeneration and Repair Laboratory, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Tamar HanochDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
Rony SegerDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.
Irina PleinesCancer and Hematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Benjamin T KileCancer and Hematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
Edna C HardemanCellular and Genetic Medicine Unit, University of New South Wales, Australia, Sydney, NSW 2052, Australia.
Peter W GunningOncology Research Unit, School of Medical Sciences, University of New South Wales, Australia, Sydney, NSW 2052, Australia p.gunning@unsw.edu.au.
UNSW Sydney · AUUniversity of Pennsylvania · USWalter and Eliza Hall Institute of Medical Research · AUWeizmann Institute of Science · ILGarvan Institute of Medical Research · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ERK-regulated cell proliferation requires multiple phosphorylation events catalyzed first by MEK and then by casein kinase 2 (CK2), followed by interaction with importin7 and subsequent nuclear translocation of pERK. We report that genetic manipulation of a core component of the actin filaments of cancer cells, the tropomyosin Tm5NM1, regulates the proliferation of normal cells both in vitro and in vivo. Mouse embryo fibroblasts (MEFs) lacking Tm5NM1, which have reduced proliferative capacity, are insensitive to inhibition of ERK by peptide and small-molecule inhibitors, indicating that ERK is unable to regulate proliferation of these knockout (KO) cells. Treatment of wild-type MEFs with a CK2 inhibitor to block phosphorylation of the nuclear translocation signal in pERK resulted in greatly decreased cell proliferation and a significant reduction in the nuclear translocation of pERK. In contrast, Tm5NM1 KO MEFs, which show reduced nuclear translocation of pERK, were unaffected by inhibition of CK2. This suggested that it is nuclear translocation of CK2-phosphorylated pERK that regulates cell proliferation and this capacity is absent in Tm5NM1 KO cells. Proximity ligation assays confirmed a growth factor-stimulated interaction of pERK with Tm5NM1 and that the interaction of pERK with importin7 is greatly reduced in the Tm5NM1 KO cells.

Indexed as

Actin CytoskeletonActive Transport, Cell NucleusAnimalsCasein Kinase IICell Line, TumorCell ProliferationHumansMaleMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicMitogen-Activated Protein Kinase KinasesPhosphorylationTropomyosinCasein Kinase IIMitogen-Activated Protein Kinase KinasesTPM3 protein, humanTpm3 protein, mouseTropomyosin

Identifiers

PMID25971798
PMCPMC4571302
OpenAlexW2258942936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.